Alaska Air Group, Inc. (NYSE:ALK) is one of the most undervalued travel stocks to buy according to hedge funds. TD Cowen cut ...

Patients with ALK+ lung cancer who had intracranial progression on ≥ 1 ALK inhibitor without measurable extracranial disease received lorlatinib 100 mg once daily. The primary end point was ...

The airline company highlighted that premium revenue increased 7% year-over-year, cargo revenue was up 22%, and loyalty revenue increased 12%. Notably, commercial initiatives and synergy capture ...

Alaska Air Group (ALK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Anne Tsao, MD: There’s an enormous paradigm shift that’s occurred in the ALK and ROS1 populations, mostly because we’ve had additional therapies that have become FDA approved. Previously we had only ...

Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-small-cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease.

If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

Despite improvements in cancer therapies in the past 50 years, neuroblastoma remains a devastating clinical problem and a leading cause of childhood cancer deaths. Advances in treatments for children ...